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ABSTRACT The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of
Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid
(DHA) in children with non-alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal
numbers to DHA 250mg/day, DHA 500mg/day or placebo. Coherently with the primary analysis, the probability of more
severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) - 59% to - 42%)] in
the combined DHA 250 and 500mg/day groups versus placebo. The present secondary analysis revealed an independent effect
of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26–
48%) for the PNPLA3M/M versus I/M genotype and lower (- 12%, 95% CI - 21% to - 3%) for the I/I versus I/M genotype
(Somers’ D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the
148I allele with greater response, to DHA supplementation in children with NAFLD.
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Following the trail of the obesity epidemics, non-alcoholic fatty liver disease (NAFLD) has become the
major cause of pediatric chronic liver disease in industrial-
ized countries, as it affects 3–10% of children, reaching
approximately 70–80% in the presence of obesity.1 NAFLD
encompasses a spectrum of liver damage ranging from
simple fat accumulation to non-alcoholic steatohepatitis
(NASH), which may evolve to cirrhosis later in life.2
Although no therapy has yet demonstrated efficacy with
regard to NASH and fibrosis,1 docosahexaenoic acid
(DHA), an omega-3 poly-unsaturated fatty acid (N3-PUFA)
with anti-inflammatory and insulin-sensitizing properties,
has shown promising results in the reduction of liver fat
content.3,4 NAFLD has a major heritable component, espe-
cially in children.5,6 In particular, the patatin-like phos-
pholipase domain-containing protein-3 (PNPLA3) rs738409
C >G polymorphism, encoding for the I148M protein vari-
ant, is not only the major genetic determinant of hepatic fat
content and increased liver enzymes7 but also a risk factor
for NASH and fibrosis.8,9 PNPLA3 is regulated by the li-
pogenic program and is involved in lipid metabolism in
hepatocytes, and the I148M polymorphism alters the ac-
tivity of this enzyme.10,11 The I148M polymorphism influ-
ences liver damage and susceptibility to NASH early in
life,5,9,12–15 synergizing with abdominal fat and carbohy-
drate intake.16,17 Interestingly, there is some evidence that
the I148M-NAFLD association is affected by the dietary N-
6-PUFA/N-3-PUFA ratio, and it has been hypothesized that
dietary supplementation with N-3-PUFA may reverse stea-
tosis in carriers of the I148M polymorphism.18 The aim of
this secondary analysis from a randomized controlled trial
(RCT)3,4 was to test whether the I148M PNPLA3 poly-
morphism is associated with the response to DHA supple-
mentation in children with NAFLD.
The study protocol and the primary analysis of this
RCT are described in detail elsewhere (trial identifier:
NCT00885313 www.clinicaltrials.gov).3,4 Briefly, 60 chil-
dren with NAFLD were randomized in equal numbers
(n = 20) to DHA 250mg/day, DHA 500mg/day, or placebo
using a parallel-arm design. Written informed consent was
obtained from the parents or legal guardians of the children,
and the study protocol was approved by the ethics com-
mittee of the Bambino Gesu` Hospital. As reported in detail
elsewhere,3,4 the primary analysis showed that DHA sup-
plementation decreased liver steatosis and that doses of 250
and 500mg/day of DHA were equally effective. PNPLA3
I148 variants were assessed at the end of the RCT by means
of 50 nuclease Taqman assays.9
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The present analysis evaluated the changes in liver fat,
triglycerides, and alanine transaminase (ALT) using Som-
ers’ D association measure.19 Somers’ D models employed
for this secondary analysis had ultrasonographically deter-
mined liver fat (discrete, 0 = none, 1 =mild, 2 =moderate,
and 3 = severe), triglycerides (continuous, mg/dL), or ALT
(continuous, U/L) as outcomes and time (discrete,
0 = baseline, 1 = 24 months), DHA (discrete, 0 = placebo,
1 = 250 or 500mg/day), a DHA · time interaction (discrete),
and PNPLA3 I148 variants (discrete, 0 = I/M, 1 =M/M,
2 = I/I) as predictors. Repeated measures were taken into
account by specifying cluster confidence intervals for each
patient. The analysis was intention to treat, and there were
no missing data. Statistical analysis was performed using
Stata 12.1 along with the somersd package.20
The main features of the patients stratified on the basis of
the PNPLA3 I148 variants are reported in Table 1. Subjects
with I/I, I/M, and M/M variants were similar for all char-
acteristics. The number of I/M, M/M, and I/I polymorphisms
in the DHA and placebo groups were 24 (71%), 13 (65%), 3
(50%) and 10 (29%), 7 (35%), 3 (50%). Figure 1 depicts the
number of subjects with liver steatosis before and after
treatment with DHA or placebo. Table 2 reports the inde-
pendent contribution of PNPLA3 I148 to the effect of DHA
on liver steatosis (Somers’ D).
Coherently with the primary analysis, the probability of
more severe steatosis after 24 months of DHA supplemen-
tation was 50% lower (95% confidence interval [CI] - 59 to
- 42%, P < .001) in the combined DHA 250 and 500mg/day
groups versus placebo. The secondary analysis, however,
revealed an independent effect of PNPLA3 on the response
to DHA. In fact, the probability of more severe steatosis was
higher (37%, 95%CI 26–48%,P< .001) for the PNPLA3M/M
versus I/M allele and lower (- 12%, 95% CI - 21 to
- 3%, P < .05) for the I/I versus I/M allele. Expectedly, the
availability on only six subjects with the I/I allele was re-
sponsible for large confidence intervals of the corresponding
effect sizes. Interestingly, the higher probability of more
severe steatosis at the end of the trial in the M/M group was
accompanied by a higher probability of increased triglyc-
erides (14%, 95% CI 1–27%) and ALT (14%, 3–25%). Even
if larger numbers of subjects are needed to precisely quan-
tify these effects,3,4 these changes are in keeping with the
known effects of DHA on serum lipids.
In this secondary analysis of an RCT,3,4 we tested whether
the PNPLA3 I148M variant is associated with the response
to DHA supplementation in children with NAFLD. We
found that the response to DHA was lower in children who
were homozygous for the 148M and higher in those who
Table 1. Baseline Measurements of the 60 Study Children
Stratified According to the I148 PNPLA3 Polymorphism
I/I
n= 6
(M= 5)
I/M
n= 34
(M= 20)
M/M
n= 20
(M = 10)
P50 IQR P50 IQR P50 IQR P value
Age (years) 10 7 11 3 12 3 .41
BMI (kg/m2) 25.5 4.2 26.0 4.4 26.7 2.3 .28
BMI (SDS) 2.1 1.2 1.8 0.7 1.9 0.6 .34
Glucose (mg/dL) 82 7 85 10 88 12 .58
Insulin (mg/dL) 17 6 10 6 13 11 .06
Triglycerides (mg/dL) 85 48 85 33 92 27 .14
ALT (U/L) 44 43 68 30 72 27 .16
P50, median; IQR, interquartile range; M, males; BMI, body mass index;
SDS, standard deviation score; ALT, alanine transaminase.
FIG. 1. Number of subjects with liver
steatosis before and after treatment with
docosahexaenoic acid (DHA) or placebo.
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were homozygous for the 148I allele as compared with
heterozygotes.
The 148M allele was associated with 50% higher proba-
bility of more severe steatosis at the end of the trial, even if
the effect of DHA on steatosis was independent from
PNPLA3. The frequency of the 148M variant in our children
was expectedly high, owing to NAFLD severity and per-
sistently elevated ALT.5,8,14,15 To our knowledge, this is the
first demonstration of a different response of NAFLD to
treatment on the basis of a genetic factor. More effective
treatments are needed for the subgroup of patients with
NAFLD homozygous for the 148M PNPLA3 variant, be-
cause the spectrum of liver disease associated with this
genetic risk factor may extend to liver cirrhosis and hepa-
tocellular carcinoma.21
In a recent study, the dietary N-6/N-3 PUFA ratio was
associated with hepatic fat content and ALT in a multi-
ethnic sample of obese children from the United States.18
Such association was evident only in subjects who were
homozygous for the 148M PNPLA3 allele, leading us to
hypothesize that the 148M allele does not allow effective
hepatic lipid remodeling in the presence of an altered dietary
N-6/N-3 PUFA ratio. These data suggest that the possibility
that the position of the last unsaturated bond of fatty acids
may be differentially affected by the 148I and 148M
PNPLA3 variants. This hypothesis needs to be addressed in
further studies, as insufficient data are available on PNPLA3
affinity for N-3 PUFA.11
A reduction of dietary N-6 PUFA or alternatively, an
increase of dietary N3-PUFA may be, therefore, needed to
correct steatosis in subjects with the 148M variant. Our data
are not consistent with the latter hypothesis, because DHA, a
N-3 PUFA, was less effective in 148M/M subjects. Our data
are more consistent with (but, of course, do not prove) the
alternative hypothesis that excessive dietary N-6 PUFA fa-
vor lipogenesis10,22 or reduce PNPLA3 hydrolytic activity or
PNPLA3 contribution to lipoprotein export11,23,24 in 148M
subjects.
The higher levels of triglycerides in 148M/M subjects
after treatment are at variance with previous results, sup-
porting an association between the 148M allele and de-
creased levels of serum triglycerides,25,26 possibly related to
impaired export of very low density lipoproteins.24 This
finding may be, however, explained by the higher severity of
steatosis, which is a major determinant of very low-density
lipoprotein secretion, in 148M/M subjects at the end of
treatment, associated with the lower response to the effect of
DHA on hepatic lipid metabolism.
Since our findings rely on an unplanned secondary anal-
ysis of an RCT, they need confirmation in specifically de-
signed RCT, where the subjects are stratified on the basis of
PNPLA3 status. However, points of strengths of the present
secondary analysis are that (1) the genetic background is
inherited and not susceptible to modification; (2) all patients
were tested; and (3) the PNPLA3 genotypes were equally
distributed among treatment arms.
In conclusion, homozygosity for the 148M PNPLA3 al-
lele is associated with lower regression of steatosis after
DHA supplementation in pediatric NAFLD. Further studies
are needed to confirm our findings and to determine the
effects of PNPLA3 on the changes of ‘‘hard’’ hepatological
outcomes such as NASH and liver fibrosis.
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